CASB.F Stock Overview
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.10 |
52 Week High | HK$4.37 |
52 Week Low | HK$1.86 |
Beta | 0.58 |
1 Month Change | 0% |
3 Month Change | 4.99% |
1 Year Change | -53.33% |
3 Year Change | -94.75% |
5 Year Change | n/a |
Change since IPO | -72.00% |
Recent News & Updates
Recent updates
Shareholder Returns
CASB.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 1.3% | 3.3% |
1Y | -53.3% | 3.0% | 25.0% |
Return vs Industry: CASB.F underperformed the US Biotechs industry which returned 3.4% over the past year.
Return vs Market: CASB.F underperformed the US Market which returned 25.8% over the past year.
Price Volatility
CASB.F volatility | |
---|---|
CASB.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CASB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CASB.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,494 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
CASB.F fundamental statistics | |
---|---|
Market cap | US$1.19b |
Earnings (TTM) | -US$209.46m |
Revenue (TTM) | US$51.33m |
12.3x
P/S Ratio-3.0x
P/E RatioIs CASB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CASB.F income statement (TTM) | |
---|---|
Revenue | CN¥370.81m |
Cost of Revenue | CN¥781.88m |
Gross Profit | -CN¥411.06m |
Other Expenses | CN¥1.10b |
Earnings | -CN¥1.51b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -6.13 |
Gross Margin | -110.85% |
Net Profit Margin | -408.10% |
Debt/Equity Ratio | 47.5% |
How did CASB.F perform over the long term?
See historical performance and comparison